hotspot -WSS

hotspot

author：focus 2025-09-29 12:29:54 - browse：845

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Readout LOUD podcast: possible new ALS drug, artificial wombs

hotspot

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

Study: New antibiotic targets gonorrhea as well as last existing drug

Diversify hospital leadership teams to protect BIPOC patient health

Extreme heat events are a public health emergency

STAT Executive Editor Rick Berke on STAT's 8th birthday

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Wikipedia

hotspot

focus

Affirmative action in medical school literally saved lives

CDC's new outbreak response network to include Northeastern

Sports medicine is finally prioritizing gender equality

Lasker Awards 2023: Winners in biomedical research

Medical records are filled with copy

Intarcia’s device

As demand for Covid shots wanes, Moderna seeks its next success

STAT Executive Editor Rick Berke on STAT's 8th birthday

Moonlake's readout produced a cash windfall. Risks remain

Will General Catalyst be the first of many hospital takeovers?

leisure time

Biotech stock slump in 2023: awaiting the turnaround

Senators: Long

A clever new way to fix Medicaid and graduate medical education

EpiPen alternative approval delay highlights citizen petition issue

Changes to biosimilar regulatory framework must prioritize patients

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

hotspot

leisure time

Wikipedia